The 2026 federal rule moved only FDA-approved and state-licensed medical marijuana to Schedule III
A DOJ/DEA final rule effective 28 April 2026 placed FDA-approved products containing marijuana, and marijuana held under a state medical licence, in Schedule III. Every other form of marijuana remains Schedule I.
We have not finished checking this source. No judgement either way. how we score evidence
Caveat on this rating: A narrow, treaty-based order; most marijuana remains Schedule I, and scheduling is not a finding of psychiatric benefit.
What the April 2026 rescheduling actually changed, in the rule's own words, because the headlines said more than the rule does.
Significant findings
Federal Register document 2026-08176 (91 FR 22714), a final rule and order published and effective 28 April 2026, "places drug products containing marijuana that have been approved by the Food and Drug Administration (FDA) in schedule III of the Controlled Substances Act". It applies to marijuana, marijuana extracts and plant-derived delta-9-THC "to the extent that any of these are included in an FDA-approved drug product or are subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes". It was issued under 21 U.S.C. 811(d)(1), the treaty-obligation route, which the order says operates "without regard to" the usual scheduling findings and procedures.
What did not change, also in its words: "any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a schedule I controlled substance". The rule "does not apply to synthetically derived THC", "does not affect the status of hemp", and is "not rescheduling any drug product containing marijuana or THC that previously has been rescheduled out of schedule I (e.g., Marinol and Syndros)."
The other direction
The order leans on an HHS evaluation that found marijuana abuse "may lead to moderate or low physical dependence" and that "the likelihood of serious outcomes is low", findings that support moving it down the schedules. It is equally clear that recreational and unlicensed marijuana stays where it was. Scheduling is a legal category about abuse potential and medical use; it is not a finding that cannabis treats any psychiatric condition.
What this does not show
It does not make cannabis an approved treatment for anxiety, depression, sleep or PTSD, and no FDA-approved product here is approved for those. It is not advice to start or stop anything.
Worth asking
If my state's medical program covers cannabis, what has the FDA actually approved, and for what?
Source
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements — Drug Enforcement Administration; US Department of Justice (2026)
Regulator or national health body
How this was scored
- Study design
- Regulatory safety determination
- Funding
- not recorded
- Published in
- Regulator or national health body
- Sample size
- not recorded
- Preregistered
- not recorded
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
We have not finished checking this source, so there is no scoring to show yet. “We have not checked this yet” and “this is disputed” are different statements, so no scored band is shown rather than a low one.
Read the full scoring rubric, including what it can't tell you.
Published October 21, 2026.
Questions
How strong is the evidence behind this?
veisund rates this source "not yet assessed". We have not finished checking this source. No judgement either way. One caveat travels with that badge: A narrow, treaty-based order; most marijuana remains Schedule I, and scheduling is not a finding of psychiatric benefit. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements — Drug Enforcement Administration; US Department of Justice (2026). Published in: Regulator or national health body. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Regulatory safety determination. Funding: not recorded. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.